Key Takeaways — Chapter 27
Core Concepts
-
Radionuclide production for medicine uses three routes: cyclotrons (proton-rich isotopes for PET: ${}^{18}\text{F}$, ${}^{11}\text{C}$, ${}^{13}\text{N}$, ${}^{15}\text{O}$), reactors (neutron-rich isotopes for therapy: ${}^{99}\text{Mo}$, ${}^{131}\text{I}$, ${}^{177}\text{Lu}$), and generators (short-lived daughters from long-lived parents: ${}^{99\text{m}}\text{Tc}$, ${}^{68}\text{Ga}$).
-
PET imaging exploits positron annihilation: $e^+ + e^- \to 2\gamma$ (511 keV each, back-to-back). Coincidence detection of the photon pair defines a line of response without a physical collimator, giving PET 10–100 times the sensitivity of SPECT.
-
${}^{18}\text{F}$-FDG is the dominant PET tracer. The nuclear physics chain: cyclotron production via ${}^{18}\text{O}(p,n){}^{18}\text{F}$ ($Q = -2.44\,\text{MeV}$) $\to$ $\beta^+$ decay ($t_{1/2} = 109.8\,\text{min}$, $E_{\max} = 634\,\text{keV}$) $\to$ positron thermalization ($\sim 0.6\,\text{mm}$ range) $\to$ annihilation $\to$ coincidence detection.
-
${}^{99\text{m}}\text{Tc}$ dominates SPECT imaging ($\sim 80\%$ of all nuclear medicine scans). Its 140.5 keV gamma ray is ideal for gamma camera detection, its 6.01-hour half-life matches clinical timescales, and the isomeric transition produces no charged-particle radiation in the patient.
-
The ${}^{99}\text{Mo}/{}^{99\text{m}}\text{Tc}$ generator is secular (nearly transient) equilibrium in clinical practice: $t_{1/2}({}^{99}\text{Mo}) = 65.94\,\text{h} \gg t_{1/2}({}^{99\text{m}}\text{Tc}) = 6.01\,\text{h}$. After milking, the daughter regrows with maximum activity at $t_{\max} \approx 22.8\,\text{h}$.
-
The Bragg peak is the clinical foundation of proton and carbon ion therapy. The $1/v^2$ dependence of the Bethe-Bloch stopping power causes charged particles to deposit maximum energy just before stopping — enabling a high tumor dose with no exit dose. This is fundamentally impossible with photon beams.
-
Carbon ions ($z = 6$) offer a sharper Bragg peak, higher LET ($\sim 100$–$200\,\text{keV}/\mu\text{m}$), higher RBE (2–4), and reduced oxygen dependence compared to protons. The trade-off is greater cost, fewer facilities, and a small fragmentation tail beyond the Bragg peak.
-
Targeted radionuclide therapy uses molecular carriers to deliver $\beta^-$ or $\alpha$ emitters directly to tumor cells. ${}^{131}\text{I}$ for thyroid cancer (the original targeted therapy, since 1941), ${}^{177}\text{Lu}$-DOTATATE for neuroendocrine tumors, ${}^{177}\text{Lu}$-PSMA-617 for prostate cancer.
-
Targeted alpha therapy (TAT) uses $\alpha$ emitters (${}^{225}\text{Ac}$, ${}^{211}\text{At}$, ${}^{212}\text{Pb}$, ${}^{223}\text{Ra}$) with range $\sim 50$–$80\,\mu\text{m}$ and LET $\sim 100\,\text{keV}/\mu\text{m}$. A single alpha traversal through a cell nucleus can produce lethal, irreparable clustered DNA damage. The daughter redistribution problem ($T_{\text{recoil}} \sim 100\,\text{keV} \gg$ bond energy) is the principal challenge.
-
The theranostic paradigm uses the same molecular platform with a diagnostic radionuclide (PET/SPECT) for imaging and a therapeutic radionuclide ($\beta^-$ or $\alpha$) for treatment. The diagnostic scan enables patient selection and dosimetry; the therapeutic radionuclide treats the disease. Example: ${}^{68}\text{Ga}$-PSMA (diagnose) $\to$ ${}^{177}\text{Lu}$-PSMA (treat).
-
Dosimetry via the MIRD formalism: $D(r_T) = \sum_{r_S} \tilde{A}(r_S) \cdot S(r_T \leftarrow r_S)$. The cumulated activity $\tilde{A}$ captures the total number of decays; the $S$-value encodes the nuclear decay data and radiation transport.
-
Effective half-life combines physical and biological clearance: $$t_{1/2,\text{eff}} = \frac{t_{1/2,\text{phys}} \times t_{1/2,\text{biol}}}{t_{1/2,\text{phys}} + t_{1/2,\text{biol}}}$$
Essential Numbers to Remember
| Quantity | Value |
|---|---|
| Annihilation photon energy | 511 keV ($= m_e c^2$) |
| ${}^{18}\text{F}$ half-life | 109.8 min |
| ${}^{18}\text{F}$ $\beta^+$ endpoint energy | 634 keV |
| ${}^{18}\text{F}$ positron range (rms, tissue) | $\sim 0.6\,\text{mm}$ |
| ${}^{99\text{m}}\text{Tc}$ half-life | 6.01 h |
| ${}^{99\text{m}}\text{Tc}$ gamma energy | 140.5 keV |
| ${}^{99}\text{Mo}$ half-life | 65.94 h |
| ${}^{131}\text{I}$ half-life | 8.02 d |
| ${}^{177}\text{Lu}$ half-life | 6.65 d |
| ${}^{225}\text{Ac}$ half-life | 10.0 d |
| ${}^{225}\text{Ac}$ total alpha energy | $\sim 28\,\text{MeV}$ (4 alphas) |
| Alpha LET in tissue | $\sim 80$–$100\,\text{keV}/\mu\text{m}$ |
| Alpha range in tissue | $\sim 50$–$80\,\mu\text{m}$ |
| Proton RBE (clinical) | $\sim 1.1$ |
| Carbon ion RBE (Bragg peak) | 2–4 |
| Range of 200 MeV protons in water | $\sim 26\,\text{cm}$ |
| Typical FDG PET dose | 370 MBq (10 mCi) |
The Threshold Concept
The same nuclear physics that makes a radionuclide useful for imaging can make its companion isotope lethal to tumor cells. The theranostic concept is not a marketing label but a direct consequence of how nuclear decay deposits energy in matter: positron emitters and gamma emitters produce penetrating radiation that exits the body (for imaging), while beta and alpha emitters produce short-range radiation that is absorbed locally (for therapy). The molecular targeting platform determines where; the nuclear physics determines what happens when it gets there.